Troisdorf

• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st … Pending
  2024-516734-35-00 5 triple-negative early breast cancer
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/ … Recruiting
  2025-522484-15-00 5 2026-04-27 ER+/HER2- early breast cancer
• A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit … Recruiting
  2025-523204-68-00 4 2026-03-25 HER2-positive breast cancer
• A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit … Recruiting
  2024-520101-39-00 5 2026-04-01 TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
• An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat … Recruiting
  2024-519913-76-00 4 2025-12-09 PDL1-negative metastatic triple-negative breast cancer
• A study of IPN10200 for the treatment of cervical dystonia in adults Recruiting
  2024-519248-34-00 4 2025-06-17 Cervical Dystonia
• Prospective randomized Phase II trial on Induction Immunochemotherapy followed by surgery or definitive chemoradiation and consolidation Dur … Recruiting
  2024-516367-80-00 4 2025-04-24 resectable and borderline resectable stage IIIA/B NSCLC
• Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer- … Recruiting
  2023-509292-17-00 4 2024-11-08 primary high-risk lobular breast cancer
• NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br … Recruiting
  2023-508787-29-00 4 2024-10-10 Triple-negative early breast cancer with low risk for recurrence
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.
• PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC Recruiting
  2023-510506-41-00 4 2024-04-15 Locally advanced, unresectable non-small-cell lung cancer (NSCLC) (Sta
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE … Recruiting
  2022-500764-35-00 6 2022-10-13 Patients with advanced HER2-negative, hormone receptor positive (HER2n
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+ … Ended recruitment
  2024-514458-61-01 4 2024-02-05 HER2+ early breast cancer
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C … Ended recruitment
  2023-505552-22-00 5 2023-02-24 Stage I-III Triple-negative Breast Cancer with residual invasive disea
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa … Ended recruitment
  2023-506911-16-00 5 2020-12-04 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Ended recruitment
  2023-509242-35-00 5 2020-07-23 HR+/HER2- early breast cancer
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk … Ended recruitment
  2024-515769-32-00 5 2019-07-02 HR+/HER2- early breast cancer
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• Interventional Platform Study Investigating the Impact of Digital Health Solutions on Health Outcomes and Health-Care Resource Utilization i … Ended
  2023-504342-55-00 10 2023-02-02 Cohort A: • Metastatic non-small cell lung carcinoma (mNSCLC) • Exten
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• CIRCULATE Ended
  2023-506715-18-00 5 2019-12-04 colon cancer stage II, rectal cancer stage II
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer
• HD21 Ended
  2024-518022-33-00 5 2016-07-15 Advanced Stage of Hodgkin Lymphoma

Showing 1–23 of 23 trials